Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

NCT01463397 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuropathic Pain

Interventions

DRUG: SAR292833
DRUG: placebo

Sponsor

Sanofi